(Reuters) – Europe’s medicines regulator said on Thursday it had initiated a rolling review of data on antibodies bamlanivimab and etesemivab being developed by U.S. company Eli Lilly to treat COVID-19.
The European Medicines Agency (EMA) said it was yet to evaluate the full dataset, adding it was too early to draw any conclusions regarding the benefit-risk balance of the medicines.
(Reporting by Muvija M in Bengaluru; Editing by Anil D’Silva)
